Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2014

View Archived Issues

Pearl Therapeutics presents first clinical data for PT-010

CytRx begins phase Ib trial of aldoxorubicin and ifosfamide or mesna

biOasis advances lysosomal storage disease program

Roche characterizes novel alpha7-nAChR PAM

Collaboration leads to state-dependent Na(v)1.7 inhibitors for the treatment of pain

rAvPAL-loaded erythrocytes as enzyme replacement therapy for phenylketonuria

Cellceutix updates on i.v. brilacidin trial and submits IND for oral rinse formulation

Aurigene Discovery Technologies divulges novel BTK inhibitors

GlaxoSmithKline discloses novel RIP-1 inhibitors

Allergan presents new S1P1 receptor modulators

Merck & Co. synthesizes new Kir1.1 channel blockers

Kala Pharmaceuticals patents novel VEGFR-2 inhibitors

Meiji Seika presents a novel antifungal with improved efficacy against dermatophytes

CURx Pharmaceuticals licenses Captisol-formulated lamotrigine from Ligand Pharmaceuticals

Eli Lilly and Boehringer Ingelheim's insulin glargine biosimilar approved in E.U.

Mimetogen releases topline data from phase III dry eye study of MIM-D3

Serodus reports phase IIa data on SER-100 in patients with systolic hypertension

NIAAA to study gabapentin enacarbil for the treatment of alcohol use disorder

Transparency Life Sciences receives grant to support phase IIa trial of lisinopril in MS

First clinical results for 2B3-201 as potential new treatment for acute relapses in MS

Senesco Technologies changes name to Sevion Therapeutics

MabVax Therapeutics receives stockholder approval for name change

Dovobet ointment launched in Japan

SRI International and Nobelpharma sign licensing agreement on SR-16234 for endometriosis

FDA approves Contrave for chronic weight management

Baxter International to name biopharmaceutical entity Baxalta

FDA advisory committee recommends approval of liraglutide for obesity

Rhodiola rosea extract proves beneficial for stress-induced sexual dysfunction in rodents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...